#oncology - Techseriesinsight

May 15, 2025
PRNewswire
Biotechnology

Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the latest data from eight hematologic malignancy clinical trials...

May 14, 2025
PRNewswire
Biotechnology

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication (https://www.biorxiv.org/cgi/content/short/2025.05.09.652772v1) of a pre-clinical ex vivo study...

May 8, 2025
PRNewswire
Biotechnology

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase...

May 6, 2025
PRNewswire
Biotechnology

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer’s Regorafenib Effect in GI Cancer Models

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has...

April 29, 2025
PRNewswire
Biotechnology

Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced that, effective April 20, 2025, the Board of Directors has appointed Sumant Ramachandra, M.D., Ph.D. as Chief...

April 25, 2025
PRNewswire
Biotechnology

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 24, 2025, the Compensation Committee of IDEAYA’s...

April 14, 2025
PRNewswire
Healthcare

Karmanos Cancer Institute Highlights Symptoms to Not Ignore During Head and Neck Cancer Awareness Month

The Barbara Ann Karmanos Cancer Institute, cancer centers, and other organizations nationwide recognize April as Head and Neck Cancer Awareness Month. Many types of cancers occur in the head and...

April 8, 2025
PRNewswire
Healthcare

Blue Faery Recognizes Excellence in Liver Cancer Research

Blue Faery: The Adrienne Wilson Liver Cancer Association announces the Blue Faery Award (BFA) for Excellence in Liver Cancer Research recipient. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), remains the...